ImmunityBio, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared

SG&A Spending Trends: ImmunityBio vs. Novavax

In the competitive landscape of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, ImmunityBio, Inc. and Novavax, Inc. have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses.

From 2014 to 2023, ImmunityBio's SG&A expenses fluctuated, peaking in 2015 with a 2,500% increase from the previous year. Meanwhile, Novavax's spending surged dramatically in 2021, marking a 105% rise compared to 2020, reflecting its aggressive market expansion and vaccine development efforts.

By 2023, Novavax's SG&A expenses were nearly 3.6 times higher than ImmunityBio's, highlighting its expansive operational scale. These trends underscore the dynamic nature of biotech financial strategies, where spending is often a precursor to innovation and market positioning.